Mark Erlander - Net Worth and Insider Trading
Mark Erlander Net Worth
The estimated net worth of Mark Erlander is at least $105,758 dollars as of 2024-12-28. Mark Erlander is the CEO of Cardiff Oncology Inc and owns about 24,481 shares of Cardiff Oncology Inc (CRDF) stock worth over $105,758. Details can be seen in Mark Erlander's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Mark Erlander has not made any transactions after 2022-11-25 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Mark Erlander
Mark Erlander Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Mark Erlander owns 1 companies in total, including Cardiff Oncology Inc (CRDF) .
Click here to see the complete history of Mark Erlander’s form 4 insider trades.
Insider Ownership Summary of Mark Erlander
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| CRDF | Cardiff Oncology Inc | 2022-11-25 | Chief Scientific Officer |
Mark Erlander Latest Holdings Summary
Mark Erlander currently owns a total of 1 stock. Mark Erlander owns 24,481 shares of Cardiff Oncology Inc (CRDF) as of November 25, 2022, with a value of $105,758.
Latest Holdings of Mark Erlander
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| CRDF | Cardiff Oncology Inc | 2022-11-25 | 24,481 | 4.32 | 105,758 |
Holding Weightings of Mark Erlander
Mark Erlander Form 4 Trading Tracker
According to the SEC Form 4 filings, Mark Erlander has made a total of 3 transactions in Cardiff Oncology Inc (CRDF) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Cardiff Oncology Inc is the acquisition of 10,000 shares on November 25, 2022, which cost Mark Erlander around $14,300.
Insider Trading History of Mark Erlander
- 1
Mark Erlander Trading Performance
GuruFocus tracks the stock performance after each of Mark Erlander's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mark Erlander is 69.07%. GuruFocus also compares Mark Erlander's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mark Erlander within 3 months outperforms 2 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Mark Erlander's insider trading performs compared to the benchmark.
Performance of Mark Erlander
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 16.34 | | | | | |
| Relative Return to S&P 500(%) | 13.84 | | | | | |
Mark Erlander Ownership Network
Mark Erlander Owned Company Details
What does Cardiff Oncology Inc do?
Who are the key executives at Cardiff Oncology Inc?
Mark Erlander is the Chief Scientific Officer of Cardiff Oncology Inc. Other key executives at Cardiff Oncology Inc include Chief Financial Officer James E. Levine , Chief Medical Officer Fairooz Kabbinavar , and Chief Scientific Officer Tod Smeal .
Cardiff Oncology Inc (CRDF) Insider Trades Summary
Over the past 18 months, Mark Erlander made no insider transaction in Cardiff Oncology Inc (CRDF). Other recent insider transactions involving Cardiff Oncology Inc (CRDF) include a net purchase of 414,565 shares made by Gary W Pace , a net purchase of 10,000 shares made by Renee P Tannenbaum , and a net purchase of 7,716 shares made by James E. Levine .
In summary, during the past 3 months, insiders sold 0 shares of Cardiff Oncology Inc (CRDF) in total and bought 379,331 shares, with a net purchase of 379,331 shares. During the past 18 months, 0 shares of Cardiff Oncology Inc (CRDF) were sold and 432,281 shares were bought by its insiders, resulting in a net purchase of 432,281 shares.
Cardiff Oncology Inc (CRDF)'s detailed insider trading history can be found in Insider Trading Tracker table.
Cardiff Oncology Inc Insider Transactions
Mark Erlander Mailing Address
Above is the net worth, insider trading, and ownership report for Mark Erlander. You might contact Mark Erlander via mailing address: C/o Trovagene, Inc., 11055 Flintkote Avenue, Suite A, San Diego Ca 92121.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
